GFAP and Alzheimer disease: Although neuroinflammation is a universal accompaniment of neurodegeneration, GFAP has been shown to reliably differentiate AD from behavioral variant frontotemporal dementia (bvFTD) with a specificity of 79% and a sensitivity of 89% [96] or from FTD and progressive supranuclear palsy with an area under the curve (AUC) of 0.84 and 0.81, respectively [97].